Aquestive Q3 Revenue Falls 41% to $7.6M; Net Loss Widens

Q3 2026 revenue fell to $7.6 million from $12.8 million a year earlier, while net loss widened to $16.5 million from $15.4 million. The FDA set a March 16, 2027 PDUFA goal date for Anaphylm; 2026 guidance was unchanged.